Gilead Sciences Inc. wants to claw back more than $4 million in legal fees the former chief financial officer of its Immunomedics unit racked up during a federal probe of insider trading allegations.
Usama Malik, 48, was CFO when Gilead bought Immunomedics for $21 billion in 2020. This year he pleaded guilty to criminal charges that he tipped off his girlfriend about a successful clinical trial for a breast-cancer drug within minutes of learning himself, allowing her to bank more than $200,000 from stock sales. Malik was sentenced to six months of home arrest and fined $15,000.
Under US ...
